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Abstract 
Background: Acute liver failure (ALF) is marked by a sudden loss of hepatic function and is associated with a high 
mortality rate in children. The etiology of ALF is shown to vary geographically. This study assessed the frequency of 
hepatotropic viruses as etiological agents of ALF in Indian children.
Methods: This retrospective study enrolled children aged 0–18 years with confirmed ALF admitted to Christian 
Medical College, Vellore and King Edward Memorial Hospital and Research Center, Pune between January 2003 and 
December 2005. The frequency of hepatotropic viruses as etiological agents in children with ALF aged ≤18 years was 
calculated with 95 % confidence interval (CI). Descriptive analyses of demographic characteristics, clinical signs and 
symptoms of ALF, choice of treatment and outcomes were performed.
Results: Of 76 children enrolled, 54 were included in the per-protocol analyses. Mean age of children with ALF was 
5.43 years (standard deviation = 3.62); 51.9 % (28/54) were female. The percentage of children positive for anti-hep-
atitis A virus (HAV) IgM and hepatitis B surface antigen was 65.9 % (27/41; 95 % CI 49.4–79.9) and 15.9 % (7/44; 95 % 
CI 6.6–30.1), respectively. The final cause of ALF was HAV (36.3 %) followed by hepatitis B virus (HBV; 8.8 %). Before 
and during admission, encephalopathy was observed in 77.8 % (42/54) and 63.0 % (34/54) of children, respectively. A 
high number of children (46/54; 85.2 %) required intensive care and ALF was fatal in 24.1 % (13/54). The proportion of 
deaths due to HAV and HBV was 18.5 % (5/27) and 57.1 % (4/7), respectively.
Conclusions: HAV and HBV were the most common etiological agents of ALF in Indian children. Primary prevention by 
vaccination against HAV and HBV in young children may be useful in the prevention of ALF due to viral hepatitis in India.
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Background
Acute liver failure (ALF) is a rare clinical syndrome marked 
by the sudden loss of hepatic function and a potentially fatal 
disease associated with a high mortality rate in children [1]. 
Worldwide, mortality associated with ALF is approximately 
70 % without appropriate management or liver transplanta-
tion [2]. ALF is characterized by coagulopathy and hepatic 
encephalopathy that occurs within 8–26  weeks of onset 
of illness in patients without any underlying liver disease 
[3]. Early signs of illness include vomiting and poor feed-
ing, while jaundice, irritability and reversal of sleep patterns 
may be variable during the early stages [2].
Currently, there are no specific therapies for ALF [1] 
except for orthotopic liver transplantation (OLT), which has 
improved survival rates from <20 % to approximately 60 % 
in ALF patients [4]. The causes of ALF include hepatotropic 
viruses, dengue, drug- and toxin-induced liver disease, and 
metabolic disorders [1, 5]. The etiology of ALF is shown to 
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vary geographically where metabolic- and drug-induced 
conditions are common causes of ALF in Europe and North 
America; and hepatitis A virus (HAV) is one of the most 
common etiological agents in Asia and South America [5]. 
Infection with hepatotropic viruses such as HAV, hepatitis 
B virus (HBV) and hepatitis E virus (HEV) are suggested to 
be the most common causes of ALF in India [6]; however, 
the etiology of ALF in children differ from that in adults [5]. 
Therefore, the identification and awareness of etiological 
agents that cause pediatric ALF may facilitate and support 
preventative and treatment measures for childhood ALF in 
India. Although, a number of studies have been conducted 
to ascertain the etiology of ALF in different parts of India 
[7–13], the data obtained has been rather inconsistent. 
This study therefore assessed the frequency of hepatotropic 
viruses as etiological agents and outcomes of ALF in medi-
cal institutions located in two diverse parts of India—cent-
ers in southern and western India using for the first time a 
similar methodology at both centers.
Methods
Study design and participants
This retrospective, hospital-based study was conducted 
in Christian Medical College (CMC), Vellore, South-
ern India and King Edward Memorial (KEM) Hospital 
and Research Center, Pune, Western India. ALF cases 
between January 2003 and December 2005 were identi-
fied through the review of hospital discharge log-books 
using International Classification of Diseases (ICD)—
9/10 codes from the admission/discharge database.
ALF was defined as cases with onset of encephalopathy 
≤28 days after the onset of symptoms [6]. Diagnosis of ALF 
was based on clinical signs and symptoms and/or laboratory 
findings of liver failure [defined as International Normalized 
Ratio above the cut-off >2 [6] and increased bilirubin (total 
bilirubin exceeding the range of normal level as specified by 
the laboratory conducting the test.)] complicated by enceph-
alopathy [or in the case of sub-acute liver failure (defined as 
cases with encephalopathy and/or ascites developing from 
29 days up to 24 weeks/6 months after the onset of symp-
toms)] in patients without a previous history of liver disease.
Children aged 0–18 years with confirmed ALF admitted 
to the selected hospitals during the retrospective review 
period (between January 2003 and December 2005) were 
included in the study. Children were excluded from the 
study if medical records were unavailable for review or 
there was insufficient information to confirm the exist-
ence or classification of ALF. The study protocol and other 
related documents were reviewed and approved by the 
investigational center Institutional Review Board. The 
study was conducted according to Good Clinical Practice, 
the Declaration of Helsinki and the International Guide-
lines for Ethical Review of Epidemiological Studies. The 
study complied with applicable regulatory requirements. 
Since the data collected from the two study center data-
bases were aggregated and de-identified in this study, no 
informed consent was required for the study.
Laboratory assays
The results of liver function tests (peak prothrombin 
time, peak total bilirubin and peak direct bilirubin) and 
tests for viral hepatitis were collected from the medical 
records of children and analyzed. Test results for liver 
enzymes, alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), total serum albumin and dengue 
fever serology were also reported descriptively.
Data Analyses
For the determination of etiological agents of ALF, the per-
protocol analyses included children identified with ALF in 
the hospital discharge log-book with no previous history of 
liver disease and whose medical records were available. The 
analysis for final causes of ALF was performed on all chil-
dren diagnosed with ALF admitted to the selected hospi-
tals during the study period. The number of ALF cases and 
the prevalence of etiological hepatotropic markers among 
ALF cases in children aged ≤18 years were reported with 
95 % confidence interval (CI). Children with viral hepatitis, 
results of laboratory tests, choice of treatment and outcomes 
of ALF were reported. Results from the physical examina-
tion, present and past medical history were also detailed. All 
statistical analyses were performed using SAS version 9.1.3.
Results
Demography
A total of 76 children were enrolled into the study, of 
which 22 children were eliminated from the per-protocol 
analyses for protocol violation with respect to inclusion/
exclusion criteria (n = 17) and for having an underlying 
medical condition not specified by the inclusion criteria 
(n = 5). Of the 54 children in the per-protocol analyses, 
63 % (34/54) and 37 % (20/54) were from KEM hospital 
and CMC hospital, respectively. Mean age of children 
with ALF was 5.4 (standard deviation: 3.62) years; 
median age was 5.0 (range 0–18) years and 51.9 % (28/54) 
of children were female. All children were Indian.
Etiological causes of viral hepatitis
Among children who were tested, 65.9 and 15.9 % were 
positive for anti-HAV IgM and hepatitis B surface anti-
gen (HBsAg), respectively. Two out of three tested chil-
dren and one out of thirty tested children were positive 
for anti-hepatitis B core (anti-HBc IgM) and anti-HEV 
IgM antibodies, respectively. None of the eight tested 
children were positive for anti-hepatitis C virus (HCV) 
(Table  1). The final cause of ALF was HAV observed in 
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36.3 % of children followed by HBV observed in 8.8 % of 
children. Other causes of ALF are shown in Fig. 1.
Assessment of liver function
The peak prothrombin time was above the normal limit 
in 74.1 % (40/54) of children; the peak total bilirubin and 
peak direct bilirubin was above the normal limit in 98.1 % 
(53/54) and 98.1  % (52/53) of children, respectively 
(Table  2). Peak ALT was above the normal limit for all 
54 children tested. The total serum albumin levels were 
below the normal limit in 82.7 % (43/52) of children.
Outcomes and treatment of ALF
Of 54 children, 85.2 % (n = 46) required intensive care. 
ALF was fatal in 24.1  % (13/54) of confirmed cases; 
61.1 % (33/54) of children recovered and were discharged 
from the hospitals while 14.8  % (8/54) of children were 
discharged and their outcome was unknown. There were 
no reports of liver transplantation in any of the children.
The proportion of deaths attributed to HAV and HBV 
was reported to be 18.5 % (5/27; 95 % CI 6.3–38.1) and 
57.1 % (4/7; 95 % CI 18.4–90.1), respectively.
Medical history and physical examination
Jaundice was reported in 88.9 % (48/54) of children. One 
child had previous history of jaundice. Nearly all children 
(96.3 %; 52/54) had no exposure to industrial solvents or 
insecticides or mushroom poisoning and 90.7 % (49/54) 
of children did not have history of medication use in the 
last 3 months. Before hospital admission, 77.8 % (42/54) 
of children had encephalopathy of which 61.9 % (26/42) 
had grade 2 encephalopathy and 26.2 % (11/42) had grade 
1 encephalopathy (Table  3). During admission, 63  % 
(34/54) of children had encephalopathy of which 47.1 % 
(16/34) had grade 5 encephalopathy (Table  3). A total 
of six children did not have encephalopathy before and 
after admission. The outcome of ALF cases related to the 
degree of encephalopathy is given in Table 4.
Of 11 children tested for dengue fever serology, 45.5 % 
(5/11; 95 % CI 16.7–76.6) and 54.5 % (6/11; 95 % CI 23.4–
83.3) tested positive for IgG and IgM, respectively.
Discussion
This study assessed the etiology of ALF at one center each in 
Southern and Western India. The results from this study add 
to the data provided by notable Indian studies conducted 
previously [7–13]. In this study, HAV was the leading cause 
of ALF (36.3 %). A higher number of children were positive 
for anti-HAV IgM compared to other viral markers. This is 
similar to a previous study that showed a higher number of 
Indian children aged 0–15 years, positive for anti-HAV IgM 
versus other viral markers [9]. Previously, a study conducted 
in Argentina concluded that in the prevaccination period, 
HAV was the leading cause of fulminant hepatic failure and 
liver transplants in the pediatric population. Following the 
introduction of the vaccine, there was a striking decrease in 
both fulminant hepatic failure and liver transplants. There 
were no new cases reported since 2007 March and this was 
a large achievement decreasing burden of disease and costs 
associated with liver transplants [14].
HBV is widely reported as a common cause of ALF in 
adults from Asian countries [15]. However, HBV contrib-
uted only to 8.8 % of ALF cases in children in this study. This 
is consistent with a previous study that suggested HBV as a 
cause of ALF is less common in children than in adults [5].
Table 1 Presence of  serological markers of  viral hepatitis 
(per-protocol) (N = 54)
a Total number of children for whom the test was done
b number (percentage) of children for whom the test result was positive
c 95 % confidence interval
d Hepatitis A virus
e Hepatitis B surface antigen
f Hepatitis B core antigen
g Hepatitis C virus
h Hepatitis E virus
Characteristics Na nb %b 95 % CIc
Anti-HAVd IgM 41 27 65.9 (49.4, 79.9)
HBs-Age 44 7 15.9 (6.6, 30.1)
Anti-HBcf IgM 3 2 66.7 (9.4, 99.2)
Anti-HCVg 8 0 0.0 (0.0, 36.9)
Anti-HEVh IgM 30 1 3.3 (0.1, 17.2)
Fig. 1 HAV, HBV and other causes of ALF (per-protocol) (N = 54). 
HAV hepatitis A virus; HBsAg hepatitis B surface antigen; HBc hepatitis 
B core antigen; HCV hepatitis C virus; HEV hepatitis E virus. Graphic 
program used: SigmaPlot 10.0
Page 4 of 7Pandit et al. BMC Res Notes  (2015) 8:381 
ALF is a severe condition given that 85.2  % of children 
suffering from ALF required intensive care. Approximately, 
24.1  % of confirmed ALF cases which proved to be fatal 
were lower than the global mortality rate (70 %) [2]. This 
finding may not reflect the true mortality rate attributed 
to ALF in India considering the children were referred to 
tertiary care, post-graduate hospitals where the specialized 
care, personnel and facilities available might have played a 
critical role in the survival of hospitalized children.
Etiology is the most important variable in predicting 
ALF outcome [6] and viruses such as HAV and HBV are 
good prognostic markers of outcomes. Another valuable 
predictor of outcome of ALF and the best indicator of 
survival is the peak prothrombin time [6, 11] which was 
observed in levels above the normal upper limit in 74.1 % 
of children. The total bilirubin peak, a useful prognos-
tic indicator [10], was above the normal limit in 98.1  % 
of children in this study. Previous studies have shown 
that prolonged prothrombin time and elevated levels of 
total bilirubin above their respective normal upper lim-
its were observed in patients who did not survive [10, 
11]. Furthermore, it was reported that 63  % of children 
had encephalopathy. Severity of encephalopathy also 
help predict outcome of ALF cases [16], suggesting that 
the risk of death increases with progression through the 
grades of encephalopathy [17]. All children who died had 
encephalopathy at some point (before/during admission) 
in this study (Table 4).
Although treatment options such as OLT have 
improved survival rates of patients with ALF, the applica-
tion is low as the treatment’s full potential has not been 
realized [18]. Determining the etiology and initial assess-
ment of prognosis is suggested to provide useful infor-
mation for ALF disease treatment and management [6]. 
HAV infection in early childhood is mostly asymptomatic 
or mildly symptomatic. Despite this acknowledgment, it 
is becoming increasingly evident that Indian children are 
susceptible to the disease in adolescence and adulthood 
Table 2 Liver function tests (per-protocol) (N = 54)
a Number (percentage) of children in each category
b Children for whom the test results were above the upper normal limit/value
c Children for whom the test results were below the lower normal limit/value
d Alanine aminotransferase
e Aspartate aminotransferase
f Milligram per milliliter
g International unit per milliliter
Parameter n (%)a Above the normal  
upper limitb n (%)a
Below the normal 
lower limitc n (%)a
Alkaline phosphatase 20 (37.0) 4 (20.0) –
Peak prothrombin time (s) 54 (100.0) 40 (74.1) 1 (1.9)
Peak total bilirubin (mg/mlf) 54 (100.0) 53 (98.1) 1 (1.9)
Peak direct bilirubin (mg/mlf) 53 (98.1) 52 (98.1) 1 (1.9)
Peak ALTd (IU/Lg) 54 (100.0) 54 (100.0) –
Peak ASTe (IU/Lg) 20 (37.0) 20 (100.0) –
Total serum albumin (g/ml) 52 (96.3) – 43 (82.7)
Table 3 Occurrence and  severity of  encephalopathy 
among children with ALF (per-protocol) (N = 54)
a Number (percentage) of children with available results
b Child was confused and had mood changes
c Child was drowsy and displayed inappropriate behavior
d Child was stuporous but obeyed simple commands
e Child was comatose but was arousable by simple commands












 No 12 22.2
During admission







 No 20 37.0
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[13], as seen in this study. Although the United States 
Advisory Committee on Immunization Practices has 
recommended universal HAV vaccination for children 
aged 12–23 months [19], vaccines against HAV in India 
are available only through private markets. Additionally, 
following the recognition of HBV as a cause of ALF, vac-
cination indicated against hepatitis B became a part of 
the national immunization program [20]. The national 
immunization programmes might start considering the 
inclusion of single-dose inactivated hepatitis A vaccines 
in their immunization schedules. This option seems to be 
comparable in terms of effectiveness, and is less expen-
sive and easier to implement than the classical 2-dose 
schedule [21]. Moreover, since encephalopathy is a late 
feature of ALF and the severity of encephalopathy has a 
poor prognosis, preventative therapy in the way of early 
recognition and appropriate management is needed [5, 
12]. Proper sanitary conditions and hygiene may help 
reduce the incidence of viral infection and timely diag-
nosis of infections due to hepatotropic viruses may help 
better manage the outcomes associated with ALF [12].
The strength of our analysis is that all hospitalized chil-
dren who were aged 0–18 years and reported ALF were 
included in this analysis. However, the findings of this 
study have to be interpreted in view of important limita-
tions. First, the target sample size of 200 children was not 
achieved as one of the planned enrollment centers—Post 
Graduate Institute of Medical Education and Research 
(PGI), Chandigarh was closed before enrollment, and 
therefore, the study population may not be representa-
tive of the entire population in India. Second, the role 
of HAV and HBV as etiological agents of ALF may have 
been underreported. The reason being that the labora-
tory tests for viral markers were not performed for all 
children included in the analysis as these tests are not 
standard practice in India. Underreporting could also be 
due to limitations in the sensitivity of HEV IgM detec-
tion system as a marker of acute infection, especially in 
children. This could not be addressed due to the retro-
spective nature of the study (Fig.  2). The retrospective 
nature of the study also meant that viral genotypes of the 
patients, the viral load, the vaccination history and other 
Table 4 Outcome of ALF cases based on severity of encephalopathy (per-protocol) (N = 54)
a Total number of children in a given category
b Number of children with available results
c Child was confused and had mood changes
d Child was drowsy and displayed inappropriate behavior
e Child was stuporous but obeyed simple commands
f Child was comatose but was arousable by simple commands
g Child was in a deep coma and did not respond to any stimuli
Time point Grade Died (N = 13)a Discharged with recovery 
(N = 33)a
Transferred out (N = 8)a Total outcomes 
(N = 54)a
nb nb nb nb
Before admission
 Yes 11 25 6 42
1c 2 7 2 11
2d 8 16 2 26
3e 1 1 2 4
4f – 1 – 1
5g – – – –
Missing – – – –
 No 2 8 2 12
During admission
 Yes 13 15 6 34
1 – 2 – 2
2 – 8 1 9
3 – 2 – 2
4 – 2 1 3
5 13 – 3 16
Missing – 1 1 2
 No – 18 2 20
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such information not available in the medical records of 
the patients could not be studied.
Conclusions
HAV was the leading cause of ALF among children in 
this study cohort. The results of this study suggest that 
a large proportion of ALF in this Indian study popula-
tion are caused by vaccine-preventable infections such as 
hepatitis A and hepatitis B. Primary prevention by vac-
cination against hepatitis A and B viruses in young chil-
dren may be useful in the prevention of ALF due to viral 
hepatitis in India.
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